Volumetric MRI versus manual segmentation in clinical trials

Yet the apparent precision of that number depends on a quieter decision made earlier in the workflow—where, exactly, the boundary of the structure was drawn, and whether the same boundary would have been drawn by another expert, or by the same expert several weeks later.

This is the central difficulty in comparing volumetric MRI with manual segmentation in clinical trials. Automated and semi-automated tools can reduce processing time and often achieve strong geometric agreement with expert annotations, but the comparison is not simply a contest between software and human judgment. It is an assessment of measurement reliability, anatomical scale, temporal consistency, and the extent to which a segmentation remains clinically meaningful when scans are repeated across months or years.

For researchers asking how to check volumetric MRI versus manual segmentation in clinical trials, the most useful answer begins with a distinction: overlap is one property of a segmentation, while reproducibility and sensitivity to biological change are others. A model can achieve a respectable Dice Similarity Coefficient and still produce boundaries that are unsuitable for a small lesion, a thin nerve, or a longitudinal endpoint where a subtle shift matters more than a large static structure.

The reliability gap: manual segmentation is a reference, not an absolute truth

Manual segmentation has traditionally occupied the position of the clinical benchmark. An experienced radiologist, neurologist, or imaging analyst reviews the scan and delineates the structure of interest slice by slice. That annotation is then used as the reference standard against which automated or semi-automated methods are evaluated.

The practical advantage is obvious: a trained human can integrate anatomical context, image artifacts, clinical information, and unusual morphology in a way that remains difficult to reproduce with a general-purpose algorithm. The less comfortable truth is that manual segmentation is not perfectly objective. The boundary is still a judgment, especially when contrast is limited, when the structure is partially obscured, or when disease has distorted the usual anatomy.

A 2023 proof-of-concept study of infant lateral ventricle volumetry illustrated the scale of this problem. Manual measurements showed inter-operator variation of up to 50% and intra-operator variation of up to 48%. When sagittal-slice manual segmentation was compared with physical three-dimensional printed phantom ground truths, errors reached as high as 71%.

These figures do not make manual segmentation useless. They clarify what it can and cannot represent. A manual label is often the best available clinical annotation, but it is not necessarily a direct measurement of biological reality. It is an observation produced by a particular reader, using a particular protocol, on a particular image series.

That distinction becomes especially important in clinical trials. If the endpoint is a change in volume between baseline and follow-up, segmentation variability can be mistaken for disease progression, treatment response, or treatment failure. A small apparent increase may reflect a different interpretation of the boundary rather than a true change in tissue. Conversely, a real but subtle change can disappear inside the noise introduced by inconsistent contouring.

The question is not whether software can replace the expert boundary; it is whether the entire measurement process can distinguish biological change from segmentation variation.

What should be measured in the comparison?

A robust comparison between volumetric MRI and manual segmentation normally examines several layers of performance rather than relying on a single similarity score:

• Geometric overlap: how much the automated and reference masks occupy the same spatial region.
• Volume agreement: whether the total measured volume is systematically larger or smaller than the reference.
• Boundary error: how far the predicted contour lies from the expert contour, particularly at clinically relevant surfaces.
• Reproducibility: whether repeated analyses produce similar results across readers, sessions, scanners, and time points.
• Processing burden: how long the workflow takes, including correction, review, and quality control.
• Clinical sensitivity: whether the measurement can detect a meaningful trajectory of disease or treatment response.

This is why a comparison framed only as automated versus manual is incomplete. The more useful comparison is between measurement systems: fully manual annotation, automated segmentation with human review, and semi-automated workflows in which the operator initializes, corrects, or accepts the result.

Performance benchmarks depend on anatomical scale

The Dice Similarity Coefficient, or DSC, is one of the most familiar metrics in medical image segmentation. It measures the degree of spatial overlap between two masks, with higher values indicating greater agreement. In large organs and sizeable lesions, automated systems commonly achieve DSC values in the range of 0.80 to 0.90 or higher when compared with expert delineations.

That range is meaningful, but it does not mean that every boundary within the mask is equally accurate. Large structures can tolerate a modest contour displacement without a dramatic reduction in total overlap. Small and elongated structures cannot. A shift of a few voxels may have little effect on a broad brainstem mask while substantially altering the apparent shape or volume of the optic nerve.

Multi-expert evaluations of intracranial structure segmentation show this anatomical dependence clearly. Larger structures, including the brainstem and eyes, produced mean DSC values of approximately 0.8–0.9 between automatic and expert delineations. Smaller tubular structures, such as the optic chiasm and optic nerves, produced lower mean DSC values of approximately 0.4–0.5.

The contrast is not evidence that the algorithm has simply failed on the smaller structures. It reflects the geometry of the problem. Small structures have fewer voxels, more partial-volume effects, less stable boundaries, and greater sensitivity to slice thickness and image noise. A slight displacement can create a large proportional volume error even when the contour appears clinically plausible.

A practical reading of common segmentation results

The prostate example is instructive because it shows that automated and manual-assisted AI approaches can both reach a mean DSC of 0.88 against expert radiologist references for whole-prostate segmentation. That is a strong result for a defined anatomical task. It should not automatically be generalized to lesion delineation, extracapsular extension, or treatment-response measurements, where the relevant boundaries are less regular and the clinical consequences of an error differ.

This shift allows us to read DSC as a starting point rather than a verdict. The score tells us how much the masks overlap. It does not tell us whether the residual error is located in a clinically important region, whether the model is biased toward under-segmentation, or whether the same error repeats consistently across follow-up scans.

Efficiency gains are most visible in longitudinal studies

The strongest argument for automated volumetric MRI in clinical research is often not that it produces a more beautiful mask. It is that it makes a longitudinal study operationally possible.

Manual segmentation becomes expensive in proportion to the number of subjects, time points, sequences, structures, and expert reviews involved. A trial that requires baseline imaging, multiple follow-up visits, central review, adjudication, and quality control may generate thousands of individual contours. Even when each scan is manageable in isolation, the cumulative burden can delay analysis and create fatigue-related inconsistency.

In a study quantifying vestibular schwannoma volume on contrast-enhanced T1 MRI, semi-automated segmentation required 167 seconds per scan, compared with 479 seconds for manual segmentation. The difference is not merely an administrative convenience. Faster processing creates room for repeat review, protocol harmonization, and more careful investigation of scans that do not fit the expected pattern.

A longitudinal prospective study of patients with CMT1A offers an even clearer example. AI-based quantitative MRI muscle segmentation, combined with human quality control, required 10 hours for the entire dataset, compared with 90 hours for fully manual segmentation. The relevant workflow was not autonomous software operating without supervision. It was a division of labor: the algorithm performed the repetitive initial delineation, while human reviewers examined and corrected the output.

That distinction matters because clinical trials do not measure only the efficiency of an individual scan. They measure trajectories. If the same segmentation method can be applied consistently across baseline and follow-up examinations, the study gains a better chance of separating gradual biological change from changes in reader behavior.

Consider the implications for diseases in which the imaging signal evolves slowly. In neuromuscular disease, subtle muscle atrophy may unfold over a period when manual contours are produced by different analysts, under different workloads, or with slightly different interpretations of fascial boundaries. In neuro-oncology, small differences in enhancing tumor margins may influence calculated volume at each visit. In developmental imaging, rapid anatomical change can make a protocol that was acceptable at one age less reliable at another.

Automation does not eliminate these sources of variation, but it can reduce the amount of repeated manual labor and create a more stable starting point for review. The gain is greatest when the protocol, preprocessing, model version, and quality-control rules remain fixed across the study.

Human quality control is part of the endpoint, not an optional afterthought

The phrase automated segmentation can give the wrong impression if it suggests that the software produces a final measurement without interpretation. In serious clinical research, the more credible model is usually human-in-the-loop segmentation.

The algorithm proposes a contour. A trained reviewer checks whether the contour follows the intended anatomy, identifies obvious failures, and corrects errors that could alter the endpoint. The corrected mask may then be stored as the final analysis object, while the original automated output is retained for audit and method development.

This arrangement has two advantages. First, it acknowledges that image acquisition is not perfectly uniform. Motion, susceptibility artifacts, altered contrast enhancement, postoperative anatomy, unusual disease morphology, and incomplete field of view can all create cases that differ from the training distribution. Second, it preserves the clinical meaning of the measurement. A mathematically plausible boundary is not necessarily the boundary that a clinician would use to answer the trial question.

Quality control should therefore be defined before the study begins, rather than left to individual preference. A useful protocol might specify:

1. Which structures require full review. A large, stable organ may be accepted after a rapid check, while a small lesion or thin nerve may require detailed slice-by-slice inspection.

2. What constitutes a correction. The study should define whether minor edge irregularities are acceptable and which anatomical deviations trigger re-segmentation.

3. How disagreements are handled. A second reader or adjudicator may be needed when the first reviewer cannot confidently resolve the boundary.

4. Which image failures lead to exclusion. Severe motion, missing sequences, poor contrast, and incomplete coverage should be recorded rather than silently folded into the analysis.

5. How software changes are controlled. A new model version or preprocessing step can alter the endpoint and should be treated as a methodological change, not a routine update.

The human reviewer is not merely cleaning up software output. The reviewer is helping define whether the measurement remains fit for the biological question.

In a longitudinal trial, quality control is not a pause between automation and analysis; it is the bridge that turns a contour into a defensible biomarker.

Beyond overlap: volume bias, surface distance, and trajectory

A segmentation can have high overlap and still produce a clinically relevant volume bias. If an algorithm consistently trims the edge of a structure, it may preserve a reasonable DSC while underestimating volume at every time point. If the same bias is stable, the model may still be useful for ranking patients or detecting relative change. If the bias varies with scanner, disease stage, or lesion morphology, the interpretation becomes more difficult.

For that reason, validation should combine overlap metrics with measurements that describe the location and magnitude of boundary errors. Depending on the anatomical task, these may include surface Dice, Hausdorff distance, average surface distance, absolute volume difference, and signed bias. The choice should follow the clinical endpoint.

A tumor-volume study may need to know whether the algorithm misses small enhancing extensions at the margin. A ventricular volumetry study may be more concerned with total volume agreement and reproducibility across time. A muscle MRI study may prioritize consistent inclusion of the same muscle compartments, even when the outer contour is less visually dramatic.

The trajectory itself also requires attention. A trial endpoint is often not the baseline volume but the change from baseline, the slope over time, or the relationship between imaging and clinical function. A segmentation method should therefore be assessed for longitudinal consistency:

• Does the model behave similarly at baseline and follow-up?
• Does a change in scanner or acquisition protocol produce a step change in volume?
• Are corrections more frequent in one treatment arm or at one disease stage?
• Does the algorithm respond to genuine atrophy, edema, hemorrhage, or enhancement in the expected direction?
• Are missing or poor-quality scans distributed unevenly across participants?

These questions move the analysis from image similarity toward biomarker validation. The purpose of a quantitative MRI measure is not simply to reproduce a mask drawn by an expert. It is to provide a measurement that remains interpretable across the biological and operational conditions of the trial.

How to compare volumetric MRI and manual segmentation in a clinical study

A useful comparison can be organized as a sequence of decisions rather than a single benchmark exercise.

1. Define the clinical question before choosing the metric

Begin with the biological event the imaging endpoint is meant to capture. Is the study measuring tumor burden, tissue loss, ventricular enlargement, muscle atrophy, or treatment-related change? The answer determines whether total volume, boundary location, compartment assignment, or rate of change should receive the greatest weight.

A segmentation method that is adequate for broad whole-organ volume may be unsuitable for a thin substructure or a focal lesion. The more closely the boundary relates to a treatment decision or mechanistic hypothesis, the more carefully surface errors should be characterized.

2. Establish a reference set that reflects the trial population

A small, highly curated validation sample can make a model appear more reliable than it will be in practice. The reference set should include the anatomical variation, disease severity, scanner diversity, and image quality expected in the actual trial.

Manual annotations remain valuable, but they should ideally involve more than one reader for at least a subset of cases. Measuring reader agreement helps establish how much apparent algorithmic error is actually within the range of human interpretation.

3. Report overlap and absolute agreement together

DSC should be accompanied by volume difference and, where relevant, surface-based metrics. A model may score well on overlap while showing a consistent positive or negative bias in volume. Conversely, a lower DSC in a small structure may not make the measurement unusable if the error is stable and clinically unimportant.

The result should be reported by anatomical structure, disease subgroup, scanner or site where relevant, and image quality category. A single pooled number can hide the cases that matter most.

4. Measure the complete workflow time

Timing should include preprocessing, initial model inference, human review, corrections, adjudication, and final export. Comparing only the time required to generate the first automated mask with the time required for a finished manual segmentation will exaggerate the practical advantage of automation.

The studies reporting 167 seconds versus 479 seconds per vestibular schwannoma scan, and 10 hours versus 90 hours for a CMT1A muscle MRI dataset, are useful precisely because they frame processing as a workflow rather than as an isolated algorithmic event.

5. Test longitudinal repeatability

If the endpoint concerns progression or response, analyze repeated scans from the same participants and, where possible, repeated segmentations by the same and different reviewers. A method should be evaluated for the stability of its change estimates, not only for its agreement at one time point.

This is particularly important when the expected biological effect is small. A subtle degradation in tissue volume may be clinically meaningful, but only if it is larger than the variation introduced by image acquisition and segmentation.

6. Preserve an audit trail

Clinical research benefits from retaining the original scan, preprocessing record, automated mask, reviewer edits, final mask, and software version. This allows investigators to distinguish model failure from review correction and to assess whether a future model update would change previously reported measurements.

The audit trail also protects the interpretability of the trial. If a result depends heavily on manual corrections, that fact should be visible in the method rather than concealed behind the label of automated analysis.

Standardizing validation without flattening clinical reality

There is understandable pressure to identify one universal metric that would allow segmentation methods to be ranked across diseases, organs, and trial phases. That approach is attractive because it simplifies reporting, but it risks confusing comparability with validity.

A DSC of 0.88 in whole-prostate segmentation and a DSC of 0.50 in optic nerve segmentation do not describe the same kind of performance. The anatomical scale, imaging contrast, clinical purpose, and consequences of error are different. A lower overlap score may be expected for a small tubular structure, while a high score in a large organ may conceal a boundary bias that matters for a particular endpoint.

Standardization is still necessary, but it should operate at several levels:

• Acquisition standardization: consistent field strength, sequence parameters, contrast timing, coverage, and positioning where feasible.
• Preprocessing standardization: harmonized registration, resampling, bias correction, and intensity handling.
• Annotation standardization: explicit anatomical definitions, reader training, and adjudication rules.
• Metric standardization: a core set of overlap, volume, and surface measures selected for the anatomical task.
• Workflow standardization: fixed quality-control thresholds, correction policies, and software versioning.
• Longitudinal standardization: methods for handling protocol changes, missing scans, and repeated measures.

This is where quantitative MRI becomes a translational discipline rather than a purely computational one. The measurement must survive contact with real clinical timelines, imperfect scans, heterogeneous participants, and the slow accumulation of biological change.

The more defensible position is neither manual nor automatic

Manual segmentation remains indispensable in many settings because it provides anatomical expertise, supports reference-standard construction, and offers a human safeguard when an algorithm encounters unfamiliar pathology. At the same time, manual work is not automatically more accurate, and the documented variability in infant ventricular measurements makes that clear.

Automated and semi-automated segmentation can produce substantial efficiency gains, particularly in large longitudinal datasets. They can also improve consistency by applying the same initial rules across scans and participants. But their value depends on validation that extends beyond an attractive overlap score and on quality control that remains connected to the clinical purpose of the trial.

The most credible approach is therefore usually a measured combination: algorithmic delineation for scale and repeatability, expert review for anatomical judgment, and a validation framework that examines the entire trajectory of the biomarker. Consider the implications for a clinical trial designed to detect a modest treatment effect. The software does not need to make every boundary perfect. It needs to make the measurement sufficiently stable, transparent, and sensitive that a change in volume can be interpreted as biology rather than workflow noise.

That is the real comparison between volumetric MRI and manual segmentation. Not whether one can be declared the winner, but whether the chosen method can follow human disease across time without losing sight of the structures, patients, and clinical decisions that give the number meaning.